Main Article Content
After decades long absence of an official consensus on the most appropriate evaluation method for in vitro skin performance of topical semisolid drugs, United States Pharmacopoeia (USP 39) finally suggested three types of testing equipment; however, all these provide data on drug release using inert synthetic membranes. Considering the need for a readily available membrane that would be more structurally similar to human skin, this paper provides a detailed protocol of a method for drug permeation assessment that uses heat-separated porcine ear epidermis and modified Franz diffusion cells. Phases that were shown to be critical for variability of the results are identified (e.g. membrane preparation), and process parameters optimized. Applicability of the method was tested on four cream samples loaded with aceclofenac as a model drug. Sample compositions were designed in such a way to provide „large“ variations (variation of the main stabilizer: natural-origin versus synthetic emulsifier) and relatively „minor“ variations (co-solvent variation: none/isopropanol/glycerol). The developed protocol is a straightforward and reliable in vitro test for the evaluation of rate and extent of drug delivery into/through the skin. Moreover, this protocol may be routinely applied even in averagely equipped laboratories during formulation development or preliminary bioequivalence assessment of generic topical semisolids.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors grant to the Publisher the following rights to the manuscript, including any supplemental material, and any parts, extracts or elements thereof:
- the right to reproduce and distribute the Manuscript in printed form, including print-on-demand;
- the right to produce prepublications, reprints, and special editions of the Manuscript;
- the right to translate the Manuscript into other languages;
- the right to reproduce the Manuscript using photomechanical or similar means including, but not limited to photocopy, and the right to distribute these reproductions;
- the right to reproduce and distribute the Manuscript electronically or optically on any and all data carriers or storage media – especially in machine readable/digitalized form on data carriers such as hard drive, CD-Rom, DVD, Blu-ray Disc (BD), Mini-Disk, data tape – and the right to reproduce and distribute the Article via these data carriers;
- the right to store the Manuscript in databases, including online databases, and the right of transmission of the Manuscript in all technical systems and modes;
- the right to make the Manuscript available to the public or to closed user groups on individual demand, for use on monitors or other readers (including e-books), and in printable form for the user, either via the internet, other online services, or via internal or external networks.
Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen ML. Pharmacokinetics-based approaches for bioequivalence evaluation of topical dermatological drug products. Clin Pharmacokinet. 2015; 54: 1095–1106.
Shah VP, Yacobi A, Rădulescu FŞ, Miron DS, Lane ME. A science based approach to topical drug classification system (TCS). Int J Pharm. 2015; 491: 21–25.
Yacobi A, Shah VP, Bashaw ED, Benfeldt E, Davit B, Ganes D, Ghosh T, Kanfer I, Kasting GB, Katz L, Lionberger R, Lu GW, Maibach HI, Pershing LK, Rackley RJ, Raw A, Shukla CG, Thakker K, Wagner N, Zovko E, Lane ME. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Pharm Res. 2014; 31: 837–846.
Nakar Y. Bioequivalence for topical products-an update. Pharm Res. 2010; 27: 2590–2601.
Concept paper on the development of a guideline on quality and equivalence of topical products. European Medicine Agency. Committee for Medicinal Products for Human use (CHMP). London, UK; 2014.
FY2015 Regulatory Science Research Report: Topical Dermatological Drug Products. http://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm512492.htm (Accessed June 20, 2017).
Simon A, Amaro MI, Healy AM, Cabral LM, de Sousa VP. Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation. Int J Pharm. 2016; 512: 234–241.
European Pharmacopoeia 9th ed. Strasbourg: Council of Europe, 2017.
The United States Pharmacopoeia 39, The National Formulary 34, Rockville: United States Pharmacopoeial Convention, 2016.
Pantelic I, Milic J, Vuleta G, Dragicevic N, Savic S. Natural emulsifiers of the alkyl polyglucoside type and their influence on the permeation of drugs. In: Dragicevic N and Maibach HI, eds. Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Modification of the Stratum Corneum. Heidelberg: Springer-Verlag; 2015: 231-250.
Barbero AM, Frasch HF. Pig and guinea pig skin as surrogates for human in vitro penetration studies: a quantitative review. Toxicol In Vitro 2009; 23: 1–13.
Selzer D, Abdel-Mottaleb MM, Hahn T, Schaefer UF, Neumann D. Finite and infinite dosing: difficulties in measurements, evaluations and predictions. Adv Drug Deliv Rev. 2013; 65: 278–294.
Engesland A, Škalko-Basnet N, Flaten GE. Phospholipid vesicle-based permeation assay and EpiSkin® in assessment of drug therapies destined for skin administration. J Pharm Sci. 2015; 104: 1119-1127.
Schäfer-Korting M, Mahmoud A, Lombardi Borgia S, Brüggener B, Kleuser B, Schreiber S, Mehnert W. Reconstructed epidermis and full-thickness skin for absorption testing: influence of the vehicles used on steroid permeation. Altern Lab Anim. 2008; 36: 441-452.
Monti D, Brini I, Tampucci S, Chetoni P, Burgalassi S, Paganuzzi D, Ghirardini A. Skin permeation and distribution of two sunscreens: a comparison between reconstituted human skin and hairless rat skin. Skin Pharmacol Physiol. 2008; 21: 318-325.
Guidance document for the conduct of skin absorption studies. Environmental Health and Safety Publications Series on Testing and Assessment No. 28, 1–31. Paris, France; Nov 2004.
Simon GA, Maibach HI. The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations–an overview. Skin Pharmacol Appl Skin Physiol. 2000; 13: 229–234.
Jacobi U, Kaiser M, Toll R, Mangelsdorf S, Audring H, Otberg N, Sterry W, Lademann J. Porcine ear skin: an in vitro model for human skin. Skin Res Technol. 2007; 23: 19–24.
Summerfield A, Meurens F, Ricklin ME. The immunology of the porcine skin and its value as a model for human skin. Mol Immunol. 2015; 66: 14-21.
Altrux-Tallau N, Pirot F, Falson F, Roberts MS, Maibach HI. Qualitative and quantitative comparison of heat separated epidermis and dermatomed skin in percutaneous absorption studies. Arch Dermatol Res. 2007; 299: 507–511.
In vitro dermal absorption rate testing of certain chemicals of interest to the occupational safety and health administration. United States Environmental Protection Agency, 40 CFR Parts 9 and 799. Fed Regist. 2004; 69(80): 22402–22441.
Abd E, Yousef SA, Pastore MN, Telaprolu K, Mohammed YH, Namjoshi S, Grice JE, Roberts MS. Skin models for the testing of transdermal drugs. Clin Pharmacol. 2016; 8: 163-176.
Mitra A, Leyes A, Manser K, Roadcap B, Mestre C, Tatosian D, Jin L, Uemura N. Use of minipig skin biopsy model as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans. J Pharm Sci. 2015; 104: 1701-1708.
Tay SL, Heng PW, Chan LW. An investigation of the chick chorioallantoic membrane as an alternative model to various biological tissues for permeation studies. J Pharm Pharmacol. 2011; 63: 1283-1289.
Zhang H, Zhu X, Shen J, Xu H, Ma M, Gu W, Jiang Q, Chen J, Duan J. Characterization of a liposome-based artificial skin membrane for in vitro permeation studies using Franz diffusion cell device. J Liposome Res. 2016; 28: 1-10.
Deutsches Arzneibuch 2006, Stuttgart: Deutscher Apotheker Verlag, 2006.
Jaksic I, Lukic M, Malenovic A, Reichl S, Hoffmann C, Müller-Goymann C, Daniels R, Savic S. Compounding of a topical drug with prospective natural surfactant-stabilized pharmaceutical bases: physicochemical and in vitro/in vivo characterization. A ketoprofen case study. Eur J Pharm Biopharm. 2012; 80: 164-175.
Pantelic I, Lukic M, Markovic B, Lusiana, Hoffmann C, Müller-Goymann C, Milic J, Daniels R, Savic S. Development of a prospective isopropyl alcohol-loaded pharmaceutical base using simultaneous in vitro/in vivo characterization methods of skin performance. Drug Dev Ind Pharm. 2014; 40: 960-971.
Pantelic I, Lukic M, Markovic B, Daniels R, Vesic S, Vuleta G, Savic S. Effect of small changes in natural origin-based emulsion systems on hydrocortisone skin absorption and performance: a comparison of two in vivo methods. Pharm Dev Technol. 2014; 19: 55-64.
Ilić T, Pantelić I, Lunter D, Đorđević S, Marković B, Ranković D, Daniels R, Savić S. Critical quality attributes, in vitro release and correlated in vitro skin permeation - in vivo tape stripping collective data for demonstrating therapeutic (non)equivalence of topical semisolids: a case study of "ready-to-use" vehicles. Int J Pharm. 2017; 528: 253-267.
Food and Drug Administration (FDA) Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001
Lane ME. Skin penetration enhancers. Int J Pharm. 2013; 447: 12-21.